ICON trial update: Ipi+Nivo combination with chemotherapy does not improve survival
In this MEDtalk, primary investigator and Oncologist Jon Amund Kyte prests the latest results from the ICON trial. ICON is a randomized phase IIb trial evaluating the efficacy and safety of chemotherapy combined with ipilimumab (Ipi) and nivolumab (Nivo) in patients with metastatic hormone receptor-positive (HER2+) breast cancer. Adding Ipi/Nivo combination to chemotherapy does not seem to improve the survival outcome, and more than half of the patients had an immune-related event (irAE).
Get access to the article
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.